Amneal Pharmaceuticals, Inc. Class A Common Stock
NASDAQ: AMRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-04-29
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for AMRX.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
AMRX historical valuation range
Where current P/E sits in AMRX's own 5Y range.
AMRX intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
AMRX valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 58.18x
P/S Ratio — History
Current: 1.35x
Is AMRX overvalued in 2026?
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) currently trades at $12.80 per share with a market capitalization of $4,083,224,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 44/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 58.2x, below its 5-year median of 59.2x.
Looking at its own history, AMRX is currently trading cheaper than 64% of the last 5Y on P/E. This places it in the 36th percentile of its historical range, a reasonable but unremarkable position.
Our discounted cash flow model estimates AMRX's intrinsic value at $34.70 per share, against the current market price of $12.80. This implies a margin of safety of +57.64%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
The Piotroski F-Score of 5/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: AMRX appears richly valued on our framework, with a Smart Value Score of 44/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is AMRX overvalued in 2026?
Based on a Smart Value Score of 44/100, AMRX appears overvalued. Current price exceeds what fundamentals currently justify.
What is AMRX's fair value?
Our DCF model estimates AMRX's intrinsic value at $34.70 per share, versus the current price of $12.80. This produces a margin of safety of +57.64%.
What P/E ratio does AMRX trade at?
AMRX trades at a P/E of 58.2x on trailing twelve-month earnings, compared to its 5-year median of 59.2x.
Is AMRX a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 44/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does AMRX's valuation compare to its history?
On P/E, AMRX currently sits in the 36th percentile of its own 5Y range. That is below its long-run median relative to where it has traded over the period.
What is AMRX's Smart Value Score?
AMRX's Smart Value Score is 44/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.